Bellicum begins dosing in Phase I trial of BPX-601 to treat pancreatic adenocarcinoma

US-based pharmaceutical company Bellicum Pharmaceuticals has begun dosing in its Phase I clinical trial (BP-012) of BPX-601 for the treatment of patients with non-resectable pancreatic adenocarcinoma.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news